Jiksak Bioengineering Inc (hereinafter referred to as Jiksak; co-CEO: Jiro Kawada) under its drug discovery project has been developing a drug delivery technology using pharmaceutical antibodies called Drug Linked Carrier (DLC) for the treatment of motor neuron diseases. The line-up of antibodies against several proteins required for DLC has been jointly developed with the leading antibody development company, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD (MBL).
Jiksak had obtained DLC data that supports the hypothesis of DLC Mode of Action, which shows that the antibodies are effective as a drug delivery system.
Further development of DLC drug delivery system will be undertaken for the benefit of patients with neurological intractable diseases.
